about
Trial watch - inhibiting PARP enzymes for anticancer therapyTrial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyCyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosisImmunomodulatory effects of cyclophosphamide and implementations for vaccine design.Macrophages transmit human immunodeficiency virus type 1 products to CD4-negative cells: involvement of matrix metalloproteinase 9.IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.LTX-315, CAPtivating immunity with necrosis.Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists.Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.An immunosurveillance mechanism controls cancer cell ploidy.Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells.Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.Consensus guidelines for the detection of immunogenic cell death.Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.Molecular Regulation of the Spindle Assembly Checkpoint by Kinases and Phosphatases.A multidisciplinary study using in vivo tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells.Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cellsReplication stress response in cancer stem cells as a target for chemotherapy
P50
Q26745673-6E6F46AE-6DF1-4EC1-9504-3C1F195D72C6Q26745686-BBD6C139-82FF-44FE-95C0-01F13E28A076Q28300987-3110FAD4-F49F-4B01-BF6A-1465311B6C0EQ34187201-6AB2CE3C-7DFE-4697-998C-43235870C7F9Q35947973-C3D128DC-ECDC-4688-BD7F-8D489ABA7D98Q36520732-B5CC57D2-4B15-4AFC-B09E-C9BE76AE2AF1Q36729558-8DAA1213-7F08-4CE5-9DA5-C7B0F336A7FAQ36957051-826A41DD-8DF0-40FE-9BE7-CE038090DE8DQ37379394-AC69EE44-CBFC-48DF-8CBC-0F1A21CE9E17Q37379408-5BD19717-3604-4508-860E-405119CDE027Q37939525-3B00357F-4166-4275-9A85-BAA4844EC330Q38115968-D158A8B9-2F5B-43DB-8A7B-D3CF3BB0C926Q38823705-BFF8D5FB-4A34-4A54-9E12-3B94BB747EDBQ39049614-9F9FC295-11D0-420C-97AB-A0E81DB52D98Q39269872-7FA89742-B025-4E62-8DDA-272B278E9989Q39822076-B843015A-3C3F-42FE-9B87-1635EF56A95AQ42182888-8A22EDB8-50CC-4150-8005-F7C4FBA52EEBQ42553556-2DCBC2EB-19A3-48AC-84DA-7E3EEC59D295Q45397464-2A73FEE7-3C53-4636-83F5-3D421E98B822Q48642636-E42DAF2C-CF1A-467D-BD0C-A711864FACDDQ51520620-676FD7F7-887D-4C1D-B1D0-344E4250E188Q57616754-D6F57163-87E6-4EE8-B875-9E4757D4401BQ60201327-E87561B0-E5CC-45F9-83BE-76E5F3748CC4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonella Sistigu
@ast
Antonella Sistigu
@en
Antonella Sistigu
@es
Antonella Sistigu
@nl
Antonella Sistigu
@sl
type
label
Antonella Sistigu
@ast
Antonella Sistigu
@en
Antonella Sistigu
@es
Antonella Sistigu
@nl
Antonella Sistigu
@sl
prefLabel
Antonella Sistigu
@ast
Antonella Sistigu
@en
Antonella Sistigu
@es
Antonella Sistigu
@nl
Antonella Sistigu
@sl
P106
P2038
Antonella_Sistigu
P21
P2798
P31
P496
0000-0002-2528-1238